Abstract
Background and purpose:
Female sex hormones may protect pre-menopausal women from sudden cardiac death. We therefore investigated the effects of the main female sex hormone, 17β-estradiol, on ischaemia-induced cardiac arrhythmias and on the L-type Ca2+ current (ICaL).
Experimental approach:
In vivo experiments were performed in pentobarbital-anaesthetized rats subjected to acute coronary artery occlusion. ICaL was measured by the whole-cell patch-clamp technique, in rat isolated ventricular myocytes.
Key results:
Acute intravenous administration of 17β-estradiol as a bolus dose followed by a continuous infusion, commencing 10 min before coronary artery occlusion, had dose-dependent antiarrhythmic activity. In female rats 300 ng kg-1 + 30 ng kg−1 min−1 17β-estradiol significantly reduced the number of ventricular premature beats (VPBs) and the incidence of ventricular fibrillation (VF). A ten fold higher dose of 17β-estradiol was required to cause similar effects in male rats. In vitro 17β-estradiol reduced peak ICaL in a concentration-dependent manner. The EC50 was ten-fold higher in male myocytes (0.66 μM) than in females (0.06 μM).
Conclusions and implications:
These results indicate that 17β-estradiol has marked dose-dependent antiarrhythmic activity that is greater in female rats than in males. A similar differential potency in blocking ICaL in myocytes from female and male rats can account for this effect. This provides an explanation for the antiarrhythmic activity of 17β-estradiol and gender-selective protection against sudden cardiac death.
Female sex hormones may protect pre-menopausal women from sudden cardiac death. We therefore investigated the effects of the main female sex hormone, 17β-estradiol, on ischaemia-induced cardiac arrhythmias and on the L-type Ca2+ current (ICaL).
Experimental approach:
In vivo experiments were performed in pentobarbital-anaesthetized rats subjected to acute coronary artery occlusion. ICaL was measured by the whole-cell patch-clamp technique, in rat isolated ventricular myocytes.
Key results:
Acute intravenous administration of 17β-estradiol as a bolus dose followed by a continuous infusion, commencing 10 min before coronary artery occlusion, had dose-dependent antiarrhythmic activity. In female rats 300 ng kg-1 + 30 ng kg−1 min−1 17β-estradiol significantly reduced the number of ventricular premature beats (VPBs) and the incidence of ventricular fibrillation (VF). A ten fold higher dose of 17β-estradiol was required to cause similar effects in male rats. In vitro 17β-estradiol reduced peak ICaL in a concentration-dependent manner. The EC50 was ten-fold higher in male myocytes (0.66 μM) than in females (0.06 μM).
Conclusions and implications:
These results indicate that 17β-estradiol has marked dose-dependent antiarrhythmic activity that is greater in female rats than in males. A similar differential potency in blocking ICaL in myocytes from female and male rats can account for this effect. This provides an explanation for the antiarrhythmic activity of 17β-estradiol and gender-selective protection against sudden cardiac death.
Original language | English |
---|---|
Pages (from-to) | 233-242 |
Number of pages | 10 |
Journal | British Journal of Pharmacology |
Volume | 149 |
DOIs | |
Publication status | Published - 2006 |
Keywords
- arrhythmias
- myocardial ischaemia
- L-type calcium current
- estradiol
- coronary artery occlusion
- cardiac myocytes